Author:
Garrett Nigel,Xu Li,Smit Erasmus,Ferns Bridget,El-Gadi Saleh,Anderson Jane
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference8 articles.
1. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial;Grinsztejn;Lancet,2007
2. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection. Results of a 48-week controlled study;Markowitz;J Acquir Immune Defic Syndr,2007
3. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection;Hazuda;Antivir Ther,2007
4. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137);McColl;Antivir Ther,2007
5. Biochemical characterizations of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518);Malet;Antivir Ther,2007
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献